Twice-a-day consumption of reconstituted grape powder provides significant long-term benefit in preserving cerebral metabolism for people with mild cognitive decline, according to research presented at the recent Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
Reconstituted grape powder may offer significant benefit for people with mild cognitive decline.
In a study recently presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference, researchers examined twice-daily consumption of reconstituted freeze-dried grape powder for one year in preserving brain metabolism.
For the prospective, randomized, placebo-controlled trial, researchers assessed brain metabolism changes via brain positron emission tomography (PET) scans with the F18-fluorodeoxyglucose (FDG) radiotracer and cognitive performance through neuropsychological assessment at baseline, six months, one year and a long-term follow-up, according to the study. The 20-patient cohort (mean age of 74.6) had at least a six-month history of mild or very mild cognitive changes and were referred by clinicians who were experienced in dementia evaluation.
Over the course of one year, the researchers noted no significant metabolic decline in any of the 47 standardized volume of interest (sVOI) areas for study participants in the grape powder cohort. In contrast, the study authors found significant declines of metabolism in 27 out of 47 sVOIs in the placebo group.
For example, patients in the placebo group had a mean metabolic change of -0.153 in the right inferior frontal cortex at one year in comparison to 0.042 in the grape powder treatment cohort. For the left inferior lateral anterior temporal cortex (ilLAT), the placebo cohort had a mean metabolic change of -0.118 in contrast to 0.034 for participants receiving the grape powder. Based on results from the durability phase of the study, the study authors noted a correlation between the metabolism decline in the ilLAT and loss of neuropsychologic performance over 3.33 years.
“ … Subjects in the active grape formulation arm (demonstrated) significant protection from longitudinal loss of cerebral metabolism that was seen in the subjects receiving the placebo formulation over the 12 months of the randomized intervention, which in turn correlated with loss of neuropsychologic performance,” wrote study co-author Daniel Silverman, M.D., Ph.D., a clinical professor of molecular and medical pharmacology at the University of California-Los Angeles (UCLA).
(Editor’s note: For related research and video interviews from the 2023 SNMMI conference, click here.)
The study authors also pointed out that statistical parametric mapping and sVOI analysis revealed sustained benefits of the grape powder use at an average of 28 months after the treatment intervention had been completed, according to the study authors.
“ … Subject who had been randomized to consume reconstituted grapes twice daily enjoyed long-term protection from longitudinal loss of metabolism compared with subjects randomized to placebo, as assessed more than two years beyond the last consumed dose of either formulation … ,” added Silverman and colleagues.
Reference
1. Lu JL, Liu SS, Alcantara AR, Varughese DV, Silverman DHS. Prospective, randomized placebo-controlled trial of long-term durability of effect of one year of grape consumption on stabilizing brain metabolism in patients with mild decline in cognition. Poster abstract presented at the 2023 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting, June 24-27, Chicago. Available at: https://am.snmmi.org/iMIS/SNMMI-AM .
SNMMI: Botox May Facilitate Relief from Dry Mouth Side Effect of PSMA-Targeted Radiopharmaceuticals
June 25th 2025For patients being treated with radiopharmaceutical agents for metastatic prostate cancer, the combination of botulinum toxin and an anti-nausea patch led to a 30 percent reduction in PSMA uptake in the salivary glands, according to preliminary research findings presented at the SNMMI conference.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
SNMMI: Can Multimodal Monitoring Bolster Outcomes with Pluvicto in Treating mCRPC?
June 22nd 2025Multimodal treatment monitoring, including SPECT/CT exams 24 hours after treatment with Lu-177 PSMA-617, may have facilitated significantly shorter therapy durations and reduced side effects in patients with mCRPC, according to a two-year study presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.